Canagliflozin Treatment in Patients with Type 2 Diabetes Mellitus
نویسندگان
چکیده
منابع مشابه
Canagliflozin Treatment in Patients with Type 2 Diabetes Mellitus
Current guidelines for treatment of type 2 diabetes mellitus (T2DM) indicate a patient-centered approach that should go beyond glycemic control. Of the many antihyperglycemic agents available for treatment of T2DM, sodium-glucose cotransporter 2 (SGLT2) inhibitors offer the advantages of reduced glycated hemoglobin (A1C), body weight (BW), and systolic blood pressure (SBP) and are associated wi...
متن کاملFactors Affecting Canagliflozin-Induced Transient Urine Volume Increase in Patients with Type 2 Diabetes Mellitus
INTRODUCTION Sodium glucose co-transporter 2 (SGLT2) inhibitors exhibit diuretic activity, which is a possible mechanism underlying the cardiovascular benefit of these inhibitors. However, the osmotic diuresis-induced increase in urine volume, and the risk of dehydration have been of concern with SGLT2 inhibitor treatment. This study aimed to investigate the mechanism underlying SGLT2 inhibitor...
متن کاملEfficacy and safety of canagliflozin in patients with type 2 diabetes mellitus living in hot climates
AIMS Patients with type 2 diabetes mellitus (T2DM) have increased risk of adverse events (AEs; e.g. dehydration, hypoglycaemia) in hot weather. This analysis assessed the efficacy and safety of canagliflozin, a sodium glucose co-transporter 2 (SGLT2) inhibitor, in patients with T2DM who live in hot climates. METHODS This post hoc analysis evaluated patients with T2DM using pooled data from fo...
متن کاملEffects of Canagliflozin on Fracture Risk in Patients With Type 2 Diabetes Mellitus.
CONTEXT Canagliflozin is a sodium glucose cotransporter 2 inhibitor developed to treat type 2 diabetes mellitus (T2DM). OBJECTIVE The purpose of this study was to describe the effects of canagliflozin on bone fracture risk. DESIGN AND SETTING This was a randomized phase 3 study in patients with T2DM. PATIENTS AND INTERVENTIONS Canagliflozin doses of 100 and 300 mg were evaluated in the ov...
متن کاملCanagliflozin reduces epicardial fat in patients with type 2 diabetes mellitus
BACKGROUND It is unknown whether canagliflozin, a selective sodium glucose co-transporter 2 inhibitor, reduces epicardial adipose tissue (EAT) thickness, which is associated with insulin resistance and is a risk factor for coronary artery disease. METHODS AND RESULTS We administered 100 mg of canagliflozin for 6 months to 13 patients with type 2 diabetes mellitus. We evaluated glycemic contro...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Clinical Medicine Insights: Endocrinology and Diabetes
سال: 2015
ISSN: 1179-5514,1179-5514
DOI: 10.4137/cmed.s31526